Eli Lilly Reports real-world evidence Data for Mirvetuximab soravtansine in Merkel cell carcinoma

Eli Lilly today announced real-world evidence results for Mirvetuximab soravtansine in patients with Merkel cell carcinoma. The study demonstrated that Mirvetuximab soravtansine reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Merkel cell carcinoma and support the continued development of Mirvetuximab soravtansine in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Mirvetuximab soravtansine was consistent with previous observations, with no new safety signals identified.